Cefotaxime Clinical Uses
Cefotaxime is a third-generation cephalosporin indicated for serious bacterial infections, with primary uses in bacterial meningitis, spontaneous bacterial peritonitis, intra-abdominal infections, and severe community-acquired infections caused by susceptible gram-negative and gram-positive organisms.
Primary Indications
Bacterial Meningitis
Cefotaxime is a first-line empirical agent for bacterial meningitis across multiple age groups 1, 2:
- Adults <60 years: Cefotaxime 2 g IV every 6 hours OR ceftriaxone 2 g every 12 hours 1
- Adults ≥60 years: Add ampicillin 2 g every 4 hours to cover Listeria monocytogenes 1
- Neonates and infants:
Key organisms covered: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli 4
Add vancomycin if penicillin-resistant pneumococci are suspected (particularly in patients from regions with high resistance rates) 1, 2.
Spontaneous Bacterial Peritonitis (SBP)
Cefotaxime is the most extensively studied antibiotic for SBP, with resolution rates of 69-98% 5:
- Standard dosing: 2 g IV every 6-8 hours 5
- Duration: 5-10 days, adjustable based on clinical response 5
- Lower dose option: 2 g every 12 hours has shown equivalent efficacy (77-79% resolution) 6, 7
The 2018 KASL guidelines specifically recommend cefotaxime as first-line therapy for community-acquired SBP, with high-quality evidence demonstrating superiority over tobramycin/ampicillin combinations 5. Recent validation studies confirm cefotaxime remains effective when guided by 48-hour therapeutic response 7.
Important caveat: For hospital-acquired SBP (>48-72 hours after admission), consider broader coverage due to increased ESBL-producing organisms (46-66% of cases) 5.
Febrile Infants (8-60 Days Old)
For well-appearing febrile infants without identified focus 8:
- 8-21 days old: Ampicillin 150 mg/kg/day divided every 8 hours PLUS cefotaxime 150 mg/kg/day divided every 8 hours (or gentamicin)
- 22-60 days old: Ceftriaxone preferred, but cefotaxime is acceptable alternative
Intra-Abdominal Infections
For mild-to-moderate infections, cefotaxime (with metronidazole) is a second-choice option 9:
- Dosing: Cefotaxime 2 g every 6-8 hours + metronidazole
- First choice: Amoxicillin-clavulanate or ampicillin-gentamicin-metronidazole
- Severe infections: Cefotaxime-metronidazole or piperacillin-tazobactam 9
Additional FDA-Approved Indications 4
Lower respiratory tract infections: Pneumonia caused by S. pneumoniae, S. aureus, E. coli, Klebsiella spp., H. influenzae, Pseudomonas spp.
Genitourinary infections:
- Complicated UTIs caused by Enterococcus, Staphylococcus, E. coli, Klebsiella, Proteus spp.
- Uncomplicated gonorrhea (including penicillinase-producing strains)
Bacteremia/Septicemia: Caused by E. coli, Klebsiella, Serratia marcescens, S. aureus, Streptococcus spp.
Skin and soft tissue infections: Including those caused by S. aureus, Streptococcus spp., Enterococcus, gram-negative organisms
Bone/joint infections: Caused by S. aureus, Streptococcus spp., Pseudomonas spp., Proteus mirabilis
Gynecologic infections: Pelvic inflammatory disease, endometritis (must add anti-chlamydial coverage as cefotaxime lacks activity against C. trachomatis) 4
Dosing Considerations
Standard Adult Dosing
- Moderate infections: 1-2 g every 8-12 hours 10, 11, 12
- Severe infections: 2 g every 4-8 hours 4
- Meningitis: 2 g every 4-6 hours 1
Renal Impairment
Model-based recommendations for pediatrics 13:
- Moderate impairment: 60% of standard dose
- Severe impairment: 48% of standard dose
Key Pharmacokinetic Properties
- Half-life: ~1 hour in adults; 3.4-4.6 hours in neonates 4
- Renal excretion: 60% unchanged, 15-25% as active desacetyl metabolite 4
- Protein binding: Significant (allows once or twice daily dosing in selected patients) 11, 12
Clinical Pearls
Advantages over ceftriaxone: No risk of pseudocholelithiasis; safer in hyperbilirubinemic neonates 10
Resistance concerns: Most ESBL-producing and carbapenemase-producing organisms are resistant 4. Consider local antibiograms when selecting empirical therapy.
Cost considerations: Generally less expensive than ceftriaxone in many settings, though institutional formulary decisions vary 10
Twice-daily dosing: Feasible for mild-to-moderate infections in selected patients, reducing administration costs 10, 11, 12